Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
ECB Signals Possible Interest Rate Move if Inflation Outlook Fails to Improve 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
S&P 500, Nasdaq Hit Record Highs as AI Stocks Rally and Strong Jobs Data Boost Confidence 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
US Stock Futures Slip as Trump Rejects Iran Peace Proposal Amid Rising Middle East Tensions 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Oil Prices Rise Amid Strait of Hormuz Tensions and U.S.-Iran Ceasefire Uncertainty 
U.S.-China Beef Trade Deal Hopes Rise Ahead of Trump-Xi Summit 
Australia Budget 2026: Smaller Deficit Expected Amid Tax Reform Push 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Wall Street Hits Record High as AI Chip Stocks and Strong U.S. Jobs Data Boost Markets 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
